Hap Trading, LLC Corbus Pharmaceuticals Holdings, Inc. Call Options Transaction History

Hap Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$0.11 - $5.46 $2,332 - $115,752	-21,200 Reduced 43.44%	27,600 $0
Q3 2022 Nov 14, 2022	SELL	$0.17 - $5.31 $544 - $16,992	-3,200 Reduced 6.15%	48,800 $0
Q2 2022 Aug 12, 2022	BUY	$0.21 - $0.53 $1,050 - $2,650	5,000 Added 10.64%	52,000 $1,000
Q1 2022 May 12, 2022	SELL	$0.32 - $0.67 $1,088 - $2,278	-3,400 Reduced 6.75%	47,000 $3,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.11 $3,420 - $6,327	5,700 Added 12.75%	50,400 $4,000
Q3 2021 Nov 10, 2021	SELL	$1.01 - $1.82 $13,029 - $23,478	-12,900 Reduced 22.4%	44,700 $6,000
Q2 2021 Aug 11, 2021	SELL	$1.39 - $2.21 $30,718 - $48,841	-22,100 Reduced 27.73%	57,600 $10,000
Q1 2021 May 14, 2021	BUY	$1.27 - $3.42 $65,151 - $175,446	51,300 Added 180.63%	79,700 $17,000
Q4 2020 Feb 16, 2021	SELL	$0.94 - $1.89 $846 - $1,701	-900 Reduced 3.07%	28,400 $3,000
Q3 2020 Nov 13, 2020	SELL	$1.5 - $9.38 $242,250 - $1.51 Million	-161,500 Reduced 84.64%	29,300 $5,000
Q2 2020 Aug 10, 2020	BUY	$4.79 - $8.39 $913,932 - $1.6 Million	190,800 New	190,800 $521,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.